Emily Murphy represents clients in a broad range of litigation and investigatory matters, including antitrust litigation and investigations, product liability and consumer protection litigation, and white collar investigations. Her experience spans a spectrum of industries including financial services, medical devices, aviation, insurance, and healthcare.
Emily has represented clients at every stage of litigation. She has briefed dispositive and pretrial motions in federal district court; supported the direct and cross-examination of witnesses at depositions and trial; and planned and executed fact discovery in several matters. In 2022, she was a key member of the antitrust trial team in AngioDynamics v. Bard.
Emily maintains an active pro bono practice, primarily focusing on immigration and voting rights cases.
- Member of team that represented C.R. Bard at trial in AngioDynamics v. Bard (N.D.N.Y), where the plaintiff sought to prove Bard had unlawfully tied its peripherially inserted central catheters to the innovative technology it invented to assist nurses during the insertion procedure. After a four week trial in 2022, the team secured a complete victory for Bard.
- Representing Asiana Airlines in its proposed sale to Korean Air Lines.
- Representing a company in response to a civil investigative demand from the Department of Justice related to competition in ticketing and concert promotion services.
- Representing a national retail bank in a regulatory inquiry initiated by the Consumer Financial Protection Bureau (CFPB) related to allegations of confusion in the autopay functionality of the bank’s online billpay system.
Admissions
Bar Admissions
- District of Columbia
Education
- Duke University, J.D., 2021: Board Member, Duke Law Journal and Mock Trial
- University of Notre Dame, 2016